Clinical Trial Update: Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine and cisplatin with or without cetuximab in EGFR-positive pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED